Drugs / Aplitabart
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04553692 | Sep 2020 → Jan 2025 | acute myeloid leukemia, chondrosarcoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, colorectal cancer | IGM Biosciences, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aplitabart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04553692 ↗ |
| Known as | IGM-8444 | “Aplitabart (IGM-8444)” NCT04553692 ↗ |
| Action | Activate | “DR5 Agonist Investigational Drug” NCT04553692 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068090 ↗ |
| Route | Intravenous | “Aplitabart will be administered intravenously” NCT04553692 ↗ |